AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RECCE PHARMACEUTICALS LTD

0.305

-0.015-4.69%

Volume:532.26K

Turnover:163.93K

Market Cap:79.91M

PE:-3.32

High:0.345

Open:0.345

Low:0.295

Close:0.320

Loading ...

Overview Company News Filings

Recce Pharmaceuticals Ltd - Placement at a$0.28 per New Share

THOMSON REUTERS

Further weakness as Recce Pharmaceuticals (ASX:RCE) drops 12% this week, taking three-year losses to 58%

Simply Wall St.

BUZZ-Australia's Recce Pharmaceuticals falls on widened loss

BRIEF-Recce Pharmaceuticals Says HY Net Loss For Period Attributable A$7.7 Million

BRIEF-Recce Pharmaceuticals Says Japan Patent Allowance For Recce Anti-Infectives

Recce Pharmaceuticals Obtains Japan Patent for Anti-Infectives

MT Newswires Live

Recce Pharmaceuticals Ltd - Japan Patent Allowance for Recce Anti-Infectives

THOMSON REUTERS

BRIEF-Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial Of Recce® 327 Gel In Acute Bacterial Skin And Skin Structure Infections, Supporting Accelerated Commercialization Pathway

Recce Pharmaceuticals Ltd - R327g Achieves 93% Primary Efficacy Endpoint in 14 Days

THOMSON REUTERS

Recce Pharmaceuticals Ltd - R327g Safe and Well Tolerated With No Serious Adverse Events

THOMSON REUTERS

Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial of Recce® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway

THOMSON REUTERS

Recce Pharmaceuticals releases positive data from Phase II trial of topical gel for skin infections

Recce Pharmaceuticals' Phase 2 Trial Shows Topical Gel Safe, Well-Tolerated

MT Newswires Live

BRIEF-Recce Pharmaceuticals Seeks Trading Halt

Recce Pharmaceuticals Ltd - Seeks Trading Halt Pending Announcement on Phase Ii Clinical Trial Data

THOMSON REUTERS

Recce Pharmaceuticals Doses All Patients in Phase Ii Trial of Recce® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Receives Approval for Phase Iii Trial of R327g for Dfis in Indonesia

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Preliminary Data Shows Complete Cure or Significant Improvement With R327g

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Full Data Analysis Expected in Q1 2025

THOMSON REUTERS

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RCE.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.305,"timestamp":1749190320000,"preClose":0.32,"halted":0,"volume":532258,"delay":0,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":181273224,"shares":262001793,"eps":-0.091765,"marketStatus":"Market Closed","change":-0.015,"latestTime":"06-06 16:12:00 AEST","open":0.345,"high":0.345,"low":0.295,"amount":163932,"amplitude":0.15625,"askPrice":0.33,"askSize":17259,"bidPrice":0.3,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":-0.091765,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.32,"openAndCloseTimeList":[[1749168000000,1749189600000]],"volumeRatio":2.7953317456301936,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":181273224,"roa":"-217.58%","roe":"-1277.62%","lyrEps":-0.099727,"volumeRatio":2.7953317456301936,"shares":262001793,"dividePrice":0,"high":0.345,"amplitude":0.15625,"preClose":0.32,"low":0.295,"week52Low":0.275,"pbRate":"-16.02","psRate":"8.33","week52High":0.614,"institutionHeld":0,"latestPrice":0.305,"committee":-0.037854,"eps":-0.091765,"divideRate":0,"volume":532258,"delay":0,"ttmEps":-0.091765,"open":0.345,"prevYearClose":0.48,"prevWeekClose":0.36,"prevMonthClose":0.36,"prevQuarterClose":0.357,"fiveDayClose":0.36,"twentyDayClose":0.28,"sixtyDayClose":0.317},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526284353","title":"Recce Pharmaceuticals Ltd -  Placement at a$0.28 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2526284353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526284353?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:44","pubTimestamp":1744242273,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUEX9FFY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2517950397","title":"Further weakness as Recce Pharmaceuticals (ASX:RCE) drops 12% this week, taking three-year losses to 58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517950397","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517950397?lang=en_us&edition=fundamental","pubTime":"2025-03-05 07:37","pubTimestamp":1741131431,"startTime":"0","endTime":"0","summary":"The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/further-weakness-as-recce-pharmaceuticals-asxrce-drops-12-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2514366902","title":"BUZZ-Australia's Recce Pharmaceuticals falls on widened loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2514366902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514366902?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:40","pubTimestamp":1740706816,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Recce Pharmaceuticals falls on widened loss** Shares of Recce Pharmaceuticals RCE.AX fall 2.3% to A$0.420, their lowest since February 21, 2024** Pharmaceutical co posts HY net loss a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ04B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2514365716","title":"BRIEF-Recce Pharmaceuticals Says HY Net Loss For Period Attributable A$7.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514365716","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514365716?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:31","pubTimestamp":1740706295,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Says HY Net Loss For Period Attributable A$7.7 MillionFeb 28 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:HY NET LOSS FOR PERIOD ATTRIBUTABLE A$7.7 MILLIONFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2514607068","title":"BRIEF-Recce Pharmaceuticals Says Japan Patent Allowance For Recce Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2514607068","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514607068?lang=en_us&edition=fundamental","pubTime":"2025-02-26 13:38","pubTimestamp":1740548287,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Says Japan Patent Allowance For Recce Anti-InfectivesFeb 26 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:JAPAN PATENT ALLOWANCE FOR RECCE ANTI-INFECTIVESFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PG11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2514071584","title":"Recce Pharmaceuticals Obtains Japan Patent for Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2514071584","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514071584?lang=en_us&edition=fundamental","pubTime":"2025-02-26 12:01","pubTimestamp":1740542472,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  received a notice of allowance from the Japan Patent Office for Patent Family 4 for its anti-infectives, according to a Wednesday filing with the Australian bourse.The claims relate to RECCE 327 and RECCE 529, which are both designed to treat bacterial and viral infections. The patent will expire in 2041.Recce Pharmaceuticals' shares were down past 2% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2514702382","title":"Recce Pharmaceuticals Ltd - Japan Patent Allowance for Recce Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2514702382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514702382?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:12","pubTimestamp":1740525172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2512485681","title":"BRIEF-Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial Of Recce® 327 Gel In Acute Bacterial Skin And Skin Structure Infections, Supporting Accelerated Commercialization Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485681","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512485681?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:03","pubTimestamp":1739977406,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial Of Recce 327 Gel In Acute Bacterial Skin And Skin Structure Infections, Supporting Accelerated Commercialization PathwayFeb 19 (Re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA1WRNVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2512101242","title":"Recce Pharmaceuticals Ltd - R327g Achieves 93% Primary Efficacy Endpoint in 14 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101242?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA1WRNVK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2512101210","title":"Recce Pharmaceuticals Ltd - R327g Safe and Well Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101210?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA1WRNVK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2512010149","title":"Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial of Recce® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2512010149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512010149?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA1WRNVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2512992976","title":"Recce Pharmaceuticals releases positive data from Phase II trial of topical gel for skin infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2512992976","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512992976?lang=en_us&edition=fundamental","pubTime":"2025-02-17 11:35","pubTimestamp":1739763313,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  has released positive patient data analysis from a Phase II clinical trial of its Recce 327 topical gel  for the treatment of acute bacterial skin and skin structure infections.The company designed the open-label trial to assess the efficacy and safety of R327G in 30 male and female patients, with one patient withdrawing due to pre-existing pain at a wound site deemed unrelated to R327G.After seven days of treatment, 25 out of the remaining 29 patients (86%) treated with R327G had a successful clinical response, while 27 patients (93%) had achieved the primary efficacy endpoint by the 14-day mark.The trial met all primary and secondary endpoints relating to the safety and tolerability, efficacy and plasma pharmacokinetics of R327G when applied directly to an infected area.Recce chief medical advisor Dr Alan Dunton said the trial results underscored the potential of R327G to meet critical unmet medical needs in infection treatment.“These results reflect the broad-","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Recce-Pharmaceutical-ASX-RCE-327-topical-gel-Phase-2-clinical-trial-results.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Recce-Pharmaceutical-ASX-RCE-327-topical-gel-Phase-2-clinical-trial-results.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/recce-pharmaceuticals-positive-data-trial-topical-gel-skin-infections/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2512600989","title":"Recce Pharmaceuticals' Phase 2 Trial Shows Topical Gel Safe, Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2512600989","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512600989?lang=en_us&edition=fundamental","pubTime":"2025-02-17 10:46","pubTimestamp":1739760362,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said phase two clinical trials of its topical gel Recce 327  for the treatment of acute bacterial skin and skin structure infections  showed that the gel is safe and well-tolerated with no serious adverse effects on patients, according to a Monday filing with the Australian bourse.After 14 days of treatment, 27 out of 29 patients treated with R327G achieved the primary efficacy endpoint, the filing said.The study's assessments observed wound healing, with the potential for full recovery after 14 days, the filing added.Based on the trial's results, experts believe the company's registrational phase 3 study for diabetic foot infections can achieve a statistically \"significant\" positive endpoint after enrolling around 100 patients, the filing added.Shares of the company rose past 2% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2511155357","title":"BRIEF-Recce Pharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2511155357","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511155357?lang=en_us&edition=fundamental","pubTime":"2025-02-13 08:58","pubTimestamp":1739408301,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Seeks Trading HaltFeb 13 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:RECCE PHARMACEUTICALS LTD - SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PHASE II CLINICAL TRIAL DATAFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P321P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2511553541","title":"Recce Pharmaceuticals Ltd -  Seeks Trading Halt Pending Announcement on Phase Ii Clinical Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2511553541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511553541?lang=en_us&edition=fundamental","pubTime":"2025-02-13 08:57","pubTimestamp":1739408264,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P321P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2505874466","title":"Recce Pharmaceuticals Doses All Patients in Phase Ii Trial of Recce® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2505874466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505874466?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA9GXJ34:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2505744215","title":"Recce Pharmaceuticals Ltd - Receives Approval for Phase Iii Trial of R327g for Dfis in Indonesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2505744215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505744215?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA9GXJ34:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2505744212","title":"Recce Pharmaceuticals Ltd - Preliminary Data Shows Complete Cure or Significant Improvement With R327g","url":"https://stock-news.laohu8.com/highlight/detail?id=2505744212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505744212?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA9GXJ34:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2505442457","title":"Recce Pharmaceuticals Ltd - Full Data Analysis Expected in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505442457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505442457?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA9GXJ34:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2505742891","title":"Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2505742891","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505742891?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327G. “R327G has made significant progress over the last year, confirming its safety profile and demonstrating impressive efficacy as a topical gel formulation, especially considering the high degree of bacterial resistance present in many of the patients being treated in this Phase II trial,” said James Graham, CEO of Recce Pharmaceuticals. “We look forward to the full dataset, which we expect will further support R327G's progress toward regulatory evaluation.”Thus far, no serious adverse events have been reported, and all patients dosed with R327G have achieved positive outcomes. The full set of data will be reviewed by the Data Safety Monitoring Board with complete results expected to be announced in Q1 2025. Recce is expected to initiate a Phase III study of R327G in Australia in H1 2025 that will serve as a registrational trial for the U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recce-pharmaceuticals-doses-patients-phase-130000740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0055631609.USD","LU0368265764.SGD","BK4533","USA","BK4213","LU0498741114.HKD","TGA.AU","BK4585","AU","LU1223082196.USD","AMR","LU1223082519.USD","BK4570","XKO.AU","LU0724618789.USD","LU0498741890.SGD","BK7096","LU0788108826.HKD","GAIN","XAO.AU","BK7001","LU1223083913.SGD","BK4522","LU0496367417.USD","BK4017","BK4588","BK4006","XJO.AU","TGA","RCE.AU","BK4135"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[]}}